{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:34:21Z","timestamp":1793698461835,"version":"4.5.1"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A cardiac condition marked by excessive growth of heart muscle cells, hypertrophic cardiomyopathy (HCM) is a complex genetic disorder characterized by left ventricular hypertrophy, microvascular ischemia, myocardial fibrosis, and diastolic dysfunction. Obstructive hypertrophic cardiomyopathy (oHCM), a subset of HCM, involves significant obstruction in the left ventricular outflow tract (LVOT), leading to symptoms like dyspnea, fatigue, and potentially life-threatening cardiac events. With advancements in genetic understanding and the introduction of novel pharmacologic agents, including cardiac myosin inhibitors like mavacamten and aficamten, there is a paradigm shift in the therapeutic approach to oHCM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>The underlying mechanisms of HCM are closely tied to genetic mutations affecting sarcomere proteins, particularly those encoded by the MYH7 and MYBPC3 genes. These mutations lead to disrupted sarcomere function, resulting in hypertrophic changes and LVOT obstruction. While genetic heterogeneity is a hallmark of HCM, clinical diagnosis relies heavily on imaging techniques such as Echocardiography and cardiac magnetic resonance imaging to assess the extent of hypertrophy and obstruction. Current pharmacological management of obstructive HCM (oHCM) focuses on alleviating symptoms rather than modifying disease progression. Beta-blockers and calcium channel blockers are primary treatment options, although their effectiveness varies among patients. Recent clinical trials have highlighted the potential of novel cardiac myosin inhibitors, including mavacamten and aficamten, in enhancing exercise capacity, reducing LVOT obstruction, and improving overall cardiac function. These innovative agents represent a significant breakthrough in targeting the fundamental pathophysiological mechanisms driving oHCM. A comprehensive literature review was conducted, utilizing top-tier databases such as PubMed, Scopus, and Google Scholar, to compile an authoritative and up-to-date overview of the current advancements in the field. This review sheds light on the updated 2024 American Heart Association (AHA) guidelines for HCM management, emphasizing the treatment cascade and tailored management for each stage of oHCM. By introducing a new paradigm for personalized medicine in oHCM, this research leverages advanced genomics, biomarkers, and imaging techniques to optimize treatment strategies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The introduction of cardiac myosin inhibitors heralds a new era in the management of oHCM. By directly targeting the molecular mechanisms underpinning the disease, these novel therapies offer improved symptom relief and functional outcomes. Ongoing research into the genetic basis of HCM and the development of targeted treatments holds promise for further enhancing patient care. Future studies should continue to refine these therapeutic strategies and explore their long-term benefits and potential in diverse patient populations. This review makes a significant contribution to the field by synthesizing the most recent AHA guidelines, emphasizing the crucial role of tailored management strategies in optimizing outcomes for patients with oHCM, and promoting the incorporation of cutting-edge genomics and imaging modalities to enhance personalized care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-024-00587-y","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T16:31:56Z","timestamp":1733589116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond"],"prefix":"10.1186","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1249-5480","authenticated-orcid":false,"given":"Khadija","family":"Sarwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2463-8009","authenticated-orcid":false,"given":"Saeeda","family":"Lashari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5577-5160","authenticated-orcid":false,"given":"Nida","family":"Rafaqat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7087-2800","authenticated-orcid":false,"family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5398-6414","authenticated-orcid":false,"given":"Abdul","family":"Raheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4049-6495","authenticated-orcid":false,"given":"Muneeb Ur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6161-2927","authenticated-orcid":false,"given":"Syed Muhammad Iraj","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"issue":"25","key":"587_CR1","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 76(25):e159\u2013e240","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"587_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121(7):749\u2013770","journal-title":"Circ Res"},{"issue":"6","key":"587_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41569-022-00682-0","volume":"19","author":"SJ Lehman","year":"2022","unstructured":"Lehman SJ, Crocini C, Leinwand LA (2022) Targeting the sarcomere in inherited cardiomyopathies. Nat Rev Cardiol 19(6):353\u2013363","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"587_CR4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 92(4):785\u2013789","journal-title":"Circulation"},{"issue":"1","key":"587_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","volume":"64","author":"BJ Maron","year":"2014","unstructured":"Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS (2014) Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64(1):83\u201399","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"587_CR6","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.amjcard.2016.02.044","volume":"117","author":"MS Maron","year":"2016","unstructured":"Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I (2016) Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Cardiol 117(10):1651\u20131654","journal-title":"Am J Cardiol"},{"issue":"12","key":"587_CR7","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65(12):1249\u20131254","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"587_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015473","volume":"9","author":"F Mazzarotto","year":"2020","unstructured":"Mazzarotto F, Olivotto I, Boschi B, Girolami F, Poggesi C, Barton PJ et al (2020) Contemporary insights into the genetics of hypertrophic cardiomyopathy: toward a new era in clinical testing? J Am Heart Assoc 9(8):e015473","journal-title":"J Am Heart Assoc"},{"issue":"25","key":"587_CR9","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1161\/CIRCULATIONAHA.121.053527","volume":"143","author":"H Watkins","year":"2021","unstructured":"Watkins H (2021) Time to think differently about sarcomere-negative hypertrophic cardiomyopathy. Circulation 143(25):2415\u20132417","journal-title":"Circulation"},{"issue":"21","key":"587_CR10","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT et al (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114(21):2232\u20132239","journal-title":"Circulation"},{"issue":"1","key":"587_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.CIR.37.1.8","volume":"37","author":"S Stewart","year":"1968","unstructured":"Stewart S, Mason DT, Braunwald E (1968) Impaired rate of left ventricular filling in idiopathic hypertrophic subaortic stenosis and valvular aortic stenosis. Circulation 37(1):8\u201314","journal-title":"Circulation"},{"issue":"12","key":"587_CR12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1161\/CIRCULATIONAHA.118.038189","volume":"139","author":"BJ Maron","year":"2019","unstructured":"Maron BJ, Rowin EJ, Maron MS (2019) Letter by Maron et al regarding article, \u201cgenotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe).\u201d Circulation 139(12):1557\u20131558","journal-title":"Circulation"},{"key":"587_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-020-01604-9","volume":"18","author":"R Capota","year":"2020","unstructured":"Capota R, Militaru S, Ionescu AA, Rosca M, Baicus C, Popescu BA et al (2020) Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire. Health Qual Life Outcomes 18:1\u20138","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"587_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","volume":"100","author":"OP Guttmann","year":"2014","unstructured":"Guttmann OP, Rahman MS, O\u2019Mahony C, Anastasakis A, Elliott PM (2014) Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 100(6):465\u2013472","journal-title":"Heart"},{"issue":"14","key":"587_CR15","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D et al (2018) Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 138(14):1387\u20131398","journal-title":"Circulation"},{"issue":"17","key":"587_CR16","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","volume":"141","author":"P Marstrand","year":"2020","unstructured":"Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M et al (2020) Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry. Circulation 141(17):1371\u20131383","journal-title":"Circulation"},{"issue":"13","key":"587_CR17","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","volume":"119","author":"P Spirito","year":"2009","unstructured":"Spirito P, Autore C, Rapezzi C, Bernab\u00f2 P, Badagliacca R, Maron MS et al (2009) Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 119(13):1703\u20131710","journal-title":"Circulation"},{"issue":"6","key":"587_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJM200002103420601","volume":"342","author":"BJ Maron","year":"2000","unstructured":"Maron BJ, Shen W-K, Link MS, Epstein AE, Almquist AK, Daubert JP et al (2000) Efficacy of implantable cardioverter\u2013defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342(6):365\u2013373","journal-title":"N Engl J Med"},{"issue":"11","key":"587_CR19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.5603\/KP.2014.0212","volume":"72","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Polish Heart J (Kardiologia Polska) 72(11):1054\u20131126","journal-title":"Polish Heart J (Kardiologia Polska)"},{"issue":"23","key":"587_CR20","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","volume":"83","author":"WC Members","year":"2024","unstructured":"Members WC, Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA et al (2024) 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 83(23):2324\u20132405","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"587_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","volume":"66","author":"BJ Maron","year":"2015","unstructured":"Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA et al (2015) Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol 66(11):1307\u20131308","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"587_CR22","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.jtcvs.2018.11.148","volume":"157","author":"K Hodges","year":"2019","unstructured":"Hodges K, Rivas CG, Aguilera J, Borden R, Alashi A, Blackstone EH et al (2019) Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. J Thorac Cardiovasc Surg 157(6):2289\u20132299","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"14","key":"587_CR23","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jacc.2016.07.735","volume":"68","author":"JH Hong","year":"2016","unstructured":"Hong JH, Schaff HV, Nishimura RA, Abel MD, Dearani JA, Li Z et al (2016) Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. J Am Coll Cardiol 68(14):1497\u20131504","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"587_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/ejcts\/ezx398","volume":"53","author":"A Nguyen","year":"2018","unstructured":"Nguyen A, Schaff HV, Nishimura RA, Dearani JA, Geske JB, Lahr BD et al (2018) Does septal thickness influence outcome of myectomy for hypertrophic obstructive cardiomyopathy? Eur J Cardiothorac Surg 53(3):582\u2013589","journal-title":"Eur J Cardiothorac Surg"},{"issue":"6","key":"587_CR25","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.athoracsur.2012.06.008","volume":"94","author":"SK Balaram","year":"2012","unstructured":"Balaram SK, Ross RE, Sherrid MV, Schwartz GS, Hillel Z, Winson G et al (2012) Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy. Ann Thorac Surg 94(6):1990\u20131998","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"587_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.21037\/acs.2017.07.07","volume":"6","author":"H Rastegar","year":"2017","unstructured":"Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE et al (2017) Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann Cardiothorac Surg 6(4):353","journal-title":"Ann Cardiothorac Surg"},{"issue":"5","key":"587_CR27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.amjcard.2014.12.017","volume":"115","author":"PA Vriesendorp","year":"2015","unstructured":"Vriesendorp PA, Schinkel AF, Soliman OI, Kofflard MJ, de Jong PL, van Herwerden LA et al (2015) Long-term benefit of myectomy and anterior mitral leaflet extension in obstructive hypertrophic cardiomyopathy. Am J Cardiol 115(5):670\u2013675","journal-title":"Am J Cardiol"},{"issue":"15","key":"587_CR28","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.jacc.2015.07.069","volume":"66","author":"P Ferrazzi","year":"2015","unstructured":"Ferrazzi P, Spirito P, Iacovoni A, Calabrese A, Migliorati K, Simon C et al (2015) Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy. J Am Coll Cardiol 66(15):1687\u20131696","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"587_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jtcvs.2003.09.040","volume":"127","author":"K Minakata","year":"2004","unstructured":"Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK (2004) Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg 127(2):481\u2013489","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"587_CR30","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.athoracsur.2008.01.061","volume":"85","author":"RK Kaple","year":"2008","unstructured":"Kaple RK, Murphy RT, DiPaola LM, Houghtaling PL, Lever HM, Lytle BW et al (2008) Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. Ann Thorac Surg 85(5):1527\u201335.e2","journal-title":"Ann Thorac Surg"},{"issue":"9","key":"587_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1161\/01.CIR.92.9.122","volume":"92","author":"FA Schoendube","year":"1995","unstructured":"Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ (1995) Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 92(9):122\u2013127","journal-title":"Circulation"},{"key":"587_CR32","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N et al (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 390:1849\u20131861","journal-title":"N Engl J Med"},{"issue":"11","key":"587_CR33","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.3390\/jcm11113083","volume":"11","author":"LF Dorobantu","year":"2022","unstructured":"Dorobantu LF, Iosifescu TA, Ticulescu R, Greavu M, Alexandrescu M, Dermengiu A et al (2022) Transaortic shallow septal myectomy and cutting of secondary fibrotic mitral valve chordae\u2014a 5-year single-center experience in the treatment of hypertrophic obstructive cardiomyopathy. J Clin Med 11(11):3083","journal-title":"J Clin Med"},{"key":"587_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.amjcard.2020.04.042","volume":"128","author":"EJ Rowin","year":"2020","unstructured":"Rowin EJ, Sridharan A, Madias C, Firely C, Koethe B, Link MS et al (2020) Prediction and prevention of sudden death in young patients (< 20 years) with hypertrophic cardiomyopathy. Am J Cardiol 128:75\u201383","journal-title":"Am J Cardiol"},{"issue":"5","key":"587_CR35","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1161\/CIRCHEARTFAILURE.113.000414","volume":"6","author":"Y Chaowu","year":"2013","unstructured":"Chaowu Y, Shihua Z, Jian L, Li L, Wei F (2013) Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy. Circ Heart Fail 6(5):1013\u20131020","journal-title":"Circ Heart Fail"},{"issue":"8","key":"587_CR36","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jacc.2009.09.047","volume":"55","author":"S Agarwal","year":"2010","unstructured":"Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW et al (2010) Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol 55(8):823\u2013834","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"587_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ccd.26293","volume":"88","author":"K Singh","year":"2016","unstructured":"Singh K, Qutub M, Carson K, Hibbert B, Glover C (2016) A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv 88(1):107\u2013115","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"587_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","volume":"142","author":"A Miron","year":"2020","unstructured":"Miron A, Lafreniere-Roula M, Steve Fan C-P, Armstrong KR, Dragulescu A, Papaz T et al (2020) A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 142(3):217\u2013229","journal-title":"Circulation"},{"issue":"10","key":"587_CR39","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1093\/europace\/euz118","volume":"21","author":"G Norrish","year":"2019","unstructured":"Norrish G, Ding T, Field E, McLeod K, Ilina M, Stuart G et al (2019) A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy. EP Europace 21(10):1559\u20131565","journal-title":"EP Europace"},{"issue":"6","key":"587_CR40","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamacardio.2018.0789","volume":"3","author":"N Maurizi","year":"2018","unstructured":"Maurizi N, Passantino S, Spaziani G, Girolami F, Arretini A, Targetti M et al (2018) Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events. JAMA Cardiol 3(6):520\u2013525","journal-title":"JAMA Cardiol"},{"issue":"10","key":"587_CR41","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.hrthm.2019.04.040","volume":"16","author":"S Balaji","year":"2019","unstructured":"Balaji S, DiLorenzo MP, Fish FA, Etheridge SP, Aziz PF, Russell MW et al (2019) Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study. Heart Rhythm 16(10):1462\u20131467","journal-title":"Heart Rhythm"},{"issue":"11","key":"587_CR42","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/2047487317702519","volume":"24","author":"G Norrish","year":"2017","unstructured":"Norrish G, Cantarutti N, Pissaridou E, Ridout DA, Limongelli G, Elliott PM et al (2017) Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis. Eur J Prev Cardiol 24(11):1220\u20131230","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"587_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.115.017633","volume":"133","author":"BJ Maron","year":"2016","unstructured":"Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, McGriff DM et al (2016) Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies. Circulation 133(1):62\u201373","journal-title":"Circulation"},{"issue":"21","key":"587_CR44","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.jacc.2015.03.552","volume":"65","author":"T Bharucha","year":"2015","unstructured":"Bharucha T, Lee KJ, Daubeney PE, Nugent AW, Turner C, Sholler GF et al (2015) Sudden death in childhood cardiomyopathy: results from a long-term national population-based study. J Am Coll Cardiol 65(21):2302\u20132310","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"587_CR45","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cge.13157","volume":"93","author":"J Mathew","year":"2018","unstructured":"Mathew J, Zahavich L, Lafreniere-Roula M, Wilson J, George K, Benson L et al (2018) Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. Clin Genet 93(2):310\u2013319","journal-title":"Clin Genet"},{"key":"587_CR46","unstructured":"FD A (2022) Approved drug proucts: CAMZYOS (mavacamten) capsules for oral use"},{"issue":"5960","key":"587_CR47","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/bmj.1.5960.708","volume":"1","author":"G Jackson","year":"1975","unstructured":"Jackson G, Atkinson L, Oram S (1975) Double-blind comparison of tolamolol, propranolol, practolol, and placebo in the treatment of angina pectoris. Br Med J 1(5960):708\u2013712","journal-title":"Br Med J"},{"key":"587_CR48","doi-asserted-by":"publisher","first-page":"ehab724.1769","DOI":"10.1093\/eurheartj\/ehab724.1769","volume":"42","author":"A Dybro","year":"2021","unstructured":"Dybro A, Rasmussen T, Nielsen R, Andersen M, Jensen M, Poulsen S (2021) Clinical effects of metoprolol in obstructive hypertrophic cardiomyopathy (TEMPO). A randomized, double-blinded, placebo-controlled crossover trial. Eur Heart J 42:ehab724.1769","journal-title":"Eur Heart J"},{"issue":"5","key":"587_CR49","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/clpt.1987.63","volume":"41","author":"J Mooy","year":"1987","unstructured":"Mooy J, van Baak M, B\u00f6hm R, Does R, Petri H, van Kemenade J et al (1987) The effects of verapamil and propranolol on exercise tolerance in hypertensive patients. Clin Pharmacol Ther 41(5):490\u2013495","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"587_CR50","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/eurheartj\/eht429","volume":"35","author":"SR Ulimoen","year":"2014","unstructured":"Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K et al (2014) Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 35(8):517\u2013524","journal-title":"Eur Heart J"},{"key":"587_CR51","doi-asserted-by":"crossref","unstructured":"Javidgonbadi D (2019) Factors in. uencing outcome in patients with obstructive hypertrophic cardiomyopathy","DOI":"10.1136\/openhrt-2018-000963"},{"issue":"44","key":"587_CR52","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","volume":"44","author":"E Braunwald","year":"2023","unstructured":"Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I (2023) Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 44(44):4622\u20134633","journal-title":"Eur Heart J"},{"issue":"1","key":"587_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7861\/clinmedicine.19-1-61","volume":"19","author":"J Firth","year":"2019","unstructured":"Firth J (2019) Cardiology: hypertrophic cardiomyopathy. Clin Med 19(1):61\u201363","journal-title":"Clin Med"},{"issue":"1","key":"587_CR54","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1530\/ERP-15-0007","volume":"2","author":"A Pantazis","year":"2015","unstructured":"Pantazis A, Vischer AS, Perez-Tome MC, Castelletti S (2015) Diagnosis and management of hypertrophic cardiomyopathy. Echo Res Pract 2(1):R45\u2013R53","journal-title":"Echo Res Pract"},{"issue":"5","key":"587_CR55","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1161\/01.CIR.85.5.1651","volume":"85","author":"HG Klues","year":"1992","unstructured":"Klues HG, Maron BJ, Dollar AL, Roberts WC (1992) Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 85(5):1651\u20131660","journal-title":"Circulation"},{"issue":"4","key":"587_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","volume":"348","author":"MS Maron","year":"2003","unstructured":"Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA et al (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348(4):295\u2013303","journal-title":"N Engl J Med"},{"issue":"30","key":"587_CR57","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","volume":"35","author":"C O'Mahony","year":"2014","unstructured":"O\u2019Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C et al (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35(30):2010\u20132020","journal-title":"Eur Heart J"},{"issue":"4","key":"587_CR58","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1161\/hc0402.102990","volume":"105","author":"H Niimura","year":"2002","unstructured":"Niimura H, Patton KK, McKenna WJ, Soults J, Maron BJ, Seidman J et al (2002) Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 105(4):446\u2013451","journal-title":"Circulation"},{"issue":"11","key":"587_CR59","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1161\/CIRCULATIONAHA.108.838672","volume":"119","author":"SJ Van Dijk","year":"2009","unstructured":"Van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JM, Winegrad S et al (2009) Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 119(11):1473\u20131483","journal-title":"Circulation"},{"issue":"6","key":"587_CR60","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.cell.2016.05.053","volume":"165","author":"MW Popp","year":"2016","unstructured":"Popp MW, Maquat LE (2016) Leveraging rules of nonsense-mediated mRNA decay for genome engineering and personalized medicine. Cell 165(6):1319\u20131322","journal-title":"Cell"},{"issue":"9","key":"587_CR61","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.4161\/rna.34406","volume":"11","author":"A Siwaszek","year":"2014","unstructured":"Siwaszek A, Ukleja M, Dziembowski A (2014) Proteins involved in the degradation of cytoplasmic mRNA in the major eukaryotic model systems. RNA Biol 11(9):1122\u20131136","journal-title":"RNA Biol"},{"issue":"7","key":"587_CR62","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1161\/CIRCRESAHA.112.270207","volume":"111","author":"SN Chen","year":"2012","unstructured":"Chen SN, Czernuszewicz G, Tan Y, Lombardi R, Jin J, Willerson JT et al (2012) Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res 111(7):907\u2013919","journal-title":"Circ Res"},{"issue":"3","key":"587_CR63","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/01.CIR.96.3.874","volume":"96","author":"R-K Li","year":"1997","unstructured":"Li R-K, Li G, Mickle DA, Weisel RD, Merante F, Luss H et al (1997) Overexpression of transforming growth factor-\u03b21 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 96(3):874\u2013881","journal-title":"Circulation"},{"issue":"22","key":"587_CR64","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1161\/CIRCULATIONAHA.115.020086","volume":"134","author":"AS Helms","year":"2016","unstructured":"Helms AS, Alvarado FJ, Yob J, Tang VT, Pagani F, Russell MW et al (2016) Genotype-dependent and-independent calcium signaling dysregulation in human hypertrophic cardiomyopathy. Circulation 134(22):1738\u20131748","journal-title":"Circulation"},{"issue":"1","key":"587_CR65","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/cvr\/cvs294","volume":"97","author":"A Ruggiero","year":"2013","unstructured":"Ruggiero A, Chen SN, Lombardi R, Rodriguez G, Marian AJ (2013) Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity. Cardiovasc Res 97(1):44\u201354","journal-title":"Cardiovasc Res"},{"issue":"11","key":"587_CR66","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1172\/JCI11093","volume":"106","author":"D Fatkin","year":"2000","unstructured":"Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IG, Schoen FJ et al (2000) An abnormal Ca 2+ response in mutant sarcomere protein\u2013mediated familial hypertrophic cardiomyopathy. J Clin Investig 106(11):1351\u20131359","journal-title":"J Clin Investig"},{"issue":"10","key":"587_CR67","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1172\/JCI42028","volume":"120","author":"P Teekakirikul","year":"2010","unstructured":"Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H et al (2010) Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-\u03b2. J Clin Investig 120(10):3520\u20133529","journal-title":"J Clin Investig"},{"issue":"3","key":"587_CR68","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/01.RES.0000177090.07296.ac","volume":"97","author":"V Senthil","year":"2005","unstructured":"Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT et al (2005) Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 97(3):285\u2013292","journal-title":"Circ Res"},{"issue":"3","key":"587_CR69","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1161\/01.CIR.104.3.317","volume":"104","author":"R Patel","year":"2001","unstructured":"Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA et al (2001) Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104(3):317\u2013324","journal-title":"Circulation"},{"key":"587_CR70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yjmcc.2013.09.012","volume":"65","author":"DW Kuster","year":"2013","unstructured":"Kuster DW, Mulders J, Ten Cate FJ, Michels M, Dos Remedios CG, da Costa Martins PA et al (2013) MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations. J Mol Cell Cardiol 65:59\u201366","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"587_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057800","volume":"8","author":"S Leptidis","year":"2013","unstructured":"Leptidis S, El Azzouzi H, Lok SI, de Weger R, Olieslagers S, Kisters N et al (2013) A deep sequencing approach to uncover the miRNOME in the human heart. PLoS ONE 8(2):e57800","journal-title":"PLoS ONE"},{"key":"587_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-015-0056-7","volume":"15","author":"W Yang","year":"2015","unstructured":"Yang W, Li Y, He F, Wu H (2015) Microarray profiling of long non-coding RNA (lncRNA) associated with hypertrophic cardiomyopathy. BMC Cardiovasc Disord 15:1\u20139","journal-title":"BMC Cardiovasc Disord"},{"issue":"9197","key":"587_CR73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0140-6736(99)06187-5","volume":"355","author":"A Marian","year":"2000","unstructured":"Marian A (2000) Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 355(9197):58\u201360","journal-title":"Lancet"},{"issue":"1","key":"587_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.stem.2012.10.010","volume":"12","author":"F Lan","year":"2013","unstructured":"Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L et al (2013) Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12(1):101\u2013113","journal-title":"Cell Stem Cell"},{"issue":"5262","key":"587_CR75","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.272.5262.731","volume":"272","author":"AA Geisterfer-Lowrance","year":"1996","unstructured":"Geisterfer-Lowrance AA, Christe M, Conner DA, Ingwall JS, Schoen FJ, Seidman CE et al (1996) A mouse model of familial hypertrophic cardiomyopathy. Science 272(5262):731\u2013734","journal-title":"Science"},{"issue":"12","key":"587_CR76","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1172\/JCI2389","volume":"101","author":"JC Tardiff","year":"1998","unstructured":"Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Moore RL et al (1998) A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Investig 101(12):2800\u20132811","journal-title":"J Clin Investig"},{"issue":"40","key":"587_CR77","doi-asserted-by":"publisher","first-page":"29575","DOI":"10.1074\/jbc.M507740200","volume":"281","author":"N Frey","year":"2006","unstructured":"Frey N, Brixius K, Schwinger RH, Benis T, Karpowski A, Lorenzen HP et al (2006) Alterations of tension-dependent ATP utilization in a transgenic rat model of hypertrophic cardiomyopathy. J Biol Chem 281(40):29575\u201329582","journal-title":"J Biol Chem"},{"issue":"8","key":"587_CR78","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1172\/JCI4088","volume":"102","author":"L Oberst","year":"1998","unstructured":"Oberst L, Zhao G, Park JT, Brugada R, Michael LH, Entman ML et al (1998) Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Investig 102(8):1498\u20131505","journal-title":"J Clin Investig"},{"issue":"12","key":"587_CR79","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1172\/JCI7956","volume":"104","author":"AJ Marian","year":"1999","unstructured":"Marian AJ, Wu Y, Lim D-S, McCluggage M, Youker K, Yu Q-t et al (1999) A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Investig 104(12):1683\u20131692","journal-title":"J Clin Investig"},{"issue":"3","key":"587_CR80","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1006\/jmcc.1999.1081","volume":"32","author":"D-S Lim","year":"2000","unstructured":"Lim D-S, Oberst L, McCluggage M, Youker K, Lacy J, DeMayo F et al (2000) Decreased left ventricular ejection fraction in transgenic mice expressing mutant cardiac troponin T-Q92, responsible for human hypertrophic cardiomyopathy. J Mol Cell Cardiol 32(3):365\u2013374","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"587_CR81","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.yjmcc.2012.03.009","volume":"52","author":"B Fraysse","year":"2012","unstructured":"Fraysse B, Weinberger F, Bardswell SC, Cuello F, Vignier N, Geertz B et al (2012) Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol 52(6):1299\u20131307","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"587_CR82","doi-asserted-by":"publisher","first-page":"H284","DOI":"10.1152\/ajpheart.00128.2007","volume":"293","author":"EP Debold","year":"2007","unstructured":"Debold EP, Schmitt JP, Patlak J, Beck S, Moore J, Seidman JG et al (2007) Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse \u03b1-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol 293(1):H284\u2013H291","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"587_CR83","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/cvr\/cvn078","volume":"79","author":"R Lombardi","year":"2008","unstructured":"Lombardi R, Bell A, Senthil V, Sidhu J, Noseda M, Roberts R et al (2008) Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res 79(1):109\u2013117","journal-title":"Cardiovasc Res"},{"key":"587_CR84","doi-asserted-by":"publisher","first-page":"I102","DOI":"10.1007\/s003950200038","volume":"97","author":"RJ Solaro","year":"2002","unstructured":"Solaro RJ, Varghese J, Marian A, Chandra M (2002) Molecular mechanisms of cardiac myofilament activation: modulation by pH and a troponin T mutant R92Q. Basic Res Cardiol 97:I102\u2013I110","journal-title":"Basic Res Cardiol"},{"issue":"11","key":"587_CR85","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1074\/jbc.M114.596676","volume":"290","author":"TM Gupte","year":"2015","unstructured":"Gupte TM, Haque F, Gangadharan B, Sunitha MS, Mukherjee S, Anandhan S et al (2015) Mechanistic heterogeneity in contractile properties of \u03b1-tropomyosin (TPM1) mutants associated with inherited cardiomyopathies. J Biol Chem 290(11):7003\u20137015","journal-title":"J Biol Chem"},{"key":"587_CR86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.yjmcc.2013.01.001","volume":"57","author":"T Kraft","year":"2013","unstructured":"Kraft T, Witjas-Paalberends ER, Boontje NM, Tripathi S, Brandis A, Montag J et al (2013) Familial hypertrophic cardiomyopathy: functional effects of myosin mutation R723G in cardiomyocytes. J Mol Cell Cardiol 57:13\u201322","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"587_CR87","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/CIRCGENETICS.113.000448","volume":"7","author":"AS Helms","year":"2014","unstructured":"Helms AS, Davis FM, Coleman D, Bartolone SN, Glazier AA, Pagani F et al (2014) Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy. Circ Cardiovasc Genet 7(4):434\u2013443","journal-title":"Circ Cardiovasc Genet"},{"issue":"3","key":"587_CR88","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/cvr\/cvt119","volume":"99","author":"ER Witjas-Paalberends","year":"2013","unstructured":"Witjas-Paalberends ER, Piroddi N, Stam K, Van Dijk SJ, Oliviera VS, Ferrara C et al (2013) Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res 99(3):432\u2013441","journal-title":"Cardiovasc Res"},{"issue":"2","key":"587_CR89","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cvr\/cvu127","volume":"103","author":"ER Witjas-Paalberends","year":"2014","unstructured":"Witjas-Paalberends ER, G\u00fc\u00e7l\u00fc A, Germans T, Knaapen P, Harms HJ, Vermeer AM et al (2014) Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc Res 103(2):248\u2013257","journal-title":"Cardiovasc Res"},{"issue":"8","key":"587_CR90","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1074\/jbc.M113.511204","volume":"289","author":"M Bloemink","year":"2014","unstructured":"Bloemink M, Deacon J, Langer S, Vera C, Combs A, Leinwand L et al (2014) The hypertrophic cardiomyopathy myosin mutation R453C alters ATP binding and hydrolysis of human cardiac \u03b2-myosin. J Biol Chem 289(8):5158\u20135167","journal-title":"J Biol Chem"},{"issue":"5","key":"587_CR91","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.yjmcc.2004.02.010","volume":"36","author":"SF Nagueh","year":"2004","unstructured":"Nagueh SF, Chen S, Patel R, Tsybouleva N, Lutucuta S, Kopelen HA et al (2004) Evolution of expression of cardiac phenotypes over a 4-year period in the \u03b2-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. J Mol Cell Cardiol 36(5):663\u2013673","journal-title":"J Mol Cell Cardiol"},{"issue":"10","key":"587_CR92","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1016\/S0021-9258(20)82162-0","volume":"259","author":"A Lompre","year":"1984","unstructured":"Lompre A, Nadal-Ginard B, Mahdavi V (1984) Expression of the cardiac ventricular alpha-and beta-myosin heavy chain genes is developmentally and hormonally regulated. J Biol Chem 259(10):6437\u20136446","journal-title":"J Biol Chem"},{"issue":"4","key":"587_CR93","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1161\/01.RES.86.4.386","volume":"86","author":"S Miyata","year":"2000","unstructured":"Miyata S, Minobe W, Bristow MR, Leinwand LA (2000) Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 86(4):386\u2013390","journal-title":"Circ Res"},{"issue":"4","key":"587_CR94","doi-asserted-by":"publisher","first-page":"H1814","DOI":"10.1152\/ajpheart.2001.280.4.H1814","volume":"280","author":"PJ Reiser","year":"2001","unstructured":"Reiser PJ, Portman MA, Ning X-H, Moravec CS (2001) Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles. Am J Physiol Heart Circ Physiol 280(4):H1814\u2013H1820","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"587_CR95","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ejmg.2010.07.007","volume":"53","author":"G Millat","year":"2010","unstructured":"Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A et al (2010) Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet 53(5):261\u2013267","journal-title":"Eur J Med Genet"},{"issue":"4","key":"587_CR96","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1034\/j.1399-0004.2003.00151.x","volume":"64","author":"J Erdmann","year":"2003","unstructured":"Erdmann J, Daehmlow S, Wischke S, Senyuva M, Werner U, Raible J et al (2003) Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet 64(4):339\u2013349","journal-title":"Clin Genet"},{"issue":"17","key":"587_CR97","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","volume":"107","author":"P Richard","year":"2003","unstructured":"Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C et al (2003) Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107(17):2227\u20132232","journal-title":"Circulation"},{"issue":"6","key":"587_CR98","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1172\/JCI116101","volume":"90","author":"A Marian","year":"1992","unstructured":"Marian A, Yu Q, Mares A, Hill R, Roberts R, Perryman M (1992) Detection of a new mutation in the beta-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy. J Clin Investig 90(6):2156\u20132165","journal-title":"J Clin Investig"},{"issue":"11","key":"587_CR99","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1172\/JCI119063","volume":"98","author":"H Watkins","year":"1996","unstructured":"Watkins H, Seidman CE, Seidman J, Feng H, Sweeney HL (1996) Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. J Clin Investig 98(11):2456\u20132461","journal-title":"J Clin Investig"},{"issue":"9","key":"587_CR100","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1161\/CIRCRESAHA.109.216291","volume":"106","author":"AJ Saltzman","year":"2010","unstructured":"Saltzman AJ, Mancini-DiNardo D, Li C, Chung WK, Ho CY, Hurst S et al (2010) The cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy. Circ Res 106(9):1549\u20131552","journal-title":"Circ Res"},{"issue":"2","key":"587_CR101","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/CIRCGENETICS.111.960831","volume":"5","author":"SP Page","year":"2012","unstructured":"Page SP, Kounas S, Syrris P, Christiansen M, Frank-Hansen R, Andersen PS et al (2012) Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age gender and long term outcome. Circ Cardiovasc Genet 5(2):156\u2013166","journal-title":"Circ Cardiovasc Genet"},{"issue":"11","key":"587_CR102","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/gim.2014.205","volume":"17","author":"AA Alfares","year":"2015","unstructured":"Alfares AA, Kelly MA, McDermott G, Funke BH, Lebo MS, Baxter SB et al (2015) Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med 17(11):880\u2013888","journal-title":"Genet Med"},{"issue":"11","key":"587_CR103","doi-asserted-by":"publisher","first-page":"H1594","DOI":"10.1152\/ajpheart.00637.2013","volume":"307","author":"A Hodatsu","year":"2014","unstructured":"Hodatsu A, Konno T, Hayashi K, Funada A, Fujita T, Nagata Y et al (2014) Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. Am J Physiol Heart Circ Physiol 307(11):H1594\u2013H1604","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"587_CR104","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1172\/JCI116900","volume":"92","author":"E Dausse","year":"1993","unstructured":"Dausse E, Komajda M, Fetler L, Dubourg O, Dufour C, Carrier L et al (1993) Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. J Clin Investig 92(6):2807\u20132813","journal-title":"J Clin Investig"},{"issue":"3","key":"587_CR105","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0735-1097(96)00538-4","volume":"29","author":"DA Coviello","year":"1997","unstructured":"Coviello DA, Maron BJ, Spirito P, Watkins H, Vosberg H-P, Thierfelder L et al (1997) Clinical features of hypertrophic cardiomyopathy caused by mutation of a \u201chot spot\u201d in the alpha-tropomyosin gene. J Am Coll Cardiol 29(3):635\u2013640","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"587_CR106","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1161\/01.CIR.94.12.3069","volume":"94","author":"JF Forissier","year":"1996","unstructured":"Forissier JF, Carrier L, Farza H, Bonne G, Bercovici J, Richard P et al (1996) Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. Circulation 94(12):3069\u20133073","journal-title":"Circulation"},{"key":"587_CR107","doi-asserted-by":"crossref","unstructured":"Bos JM, Will ML, Gersh BJ, Kruisselbrink TM, Ommen SR, Ackerman MJ (eds) (2014) Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. In: Mayo clinic proceedings. Elsevier, Amsterdam","DOI":"10.1016\/j.mayocp.2014.01.025"},{"issue":"2","key":"587_CR108","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/gim.2016.90","volume":"19","author":"R Walsh","year":"2017","unstructured":"Walsh R, Thomson KL, Ware JS, Funke BH, Woodley J, McGuire KJ et al (2017) Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med 19(2):192\u2013203","journal-title":"Genet Med"},{"issue":"46","key":"587_CR109","first-page":"3461","volume":"38","author":"R Walsh","year":"2017","unstructured":"Walsh R, Buchan R, Wilk A, John S, Felkin LE, Thomson KL et al (2017) Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur Heart J 38(46):3461\u20133468","journal-title":"Eur Heart J"},{"issue":"6","key":"587_CR110","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/clc.22404","volume":"38","author":"B Ay\u00e7a","year":"2015","unstructured":"Ay\u00e7a B, Sahin I, Kucuk SH, Akin F, Kafadar D, Av\u015far M et al (2015) Increased transforming growth factor-\u03b2 levels associated with cardiac adverse events in hypertrophic cardiomyopathy. Clin Cardiol 38(6):371\u2013377","journal-title":"Clin Cardiol"},{"issue":"1","key":"587_CR111","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.amjcard.2017.03.252","volume":"120","author":"Y Guo","year":"2017","unstructured":"Guo Y, Wu X, Zheng X, Lu J, Wang S, Huang X (2017) Usefulness of preoperative transforming growth factor-beta to predict new onset atrial fibrillation after surgical ventricular septal myectomy in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 120(1):118\u2013123","journal-title":"Am J Cardiol"},{"issue":"2","key":"587_CR112","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/15321819.2017.1344130","volume":"39","author":"S Jumaah","year":"2018","unstructured":"Jumaah S, \u00c7elekli A, Sucu M (2018) The role of human urotensin-II in patients with hypertrophic cardiomyopathy. J Immunoassay Immunochem 39(2):150\u2013162","journal-title":"J Immunoassay Immunochem"},{"issue":"7","key":"587_CR113","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1139\/cjpp-2019-0636","volume":"98","author":"A Zhu","year":"2020","unstructured":"Zhu A, Bews H, Cheung D, Nagalingam RS, Mittal I, Goyal V et al (2020) Scleraxis as a prognostic marker of myocardial fibrosis in hypertrophic cardiomyopathy (SPARC) study. Can J Physiol Pharmacol 98(7):459\u2013465","journal-title":"Can J Physiol Pharmacol"},{"issue":"4","key":"587_CR114","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00059-017-4645-3","volume":"44","author":"J Podzimkova","year":"2019","unstructured":"Podzimkova J, Palecek T, Kuchynka P, Marek J, Danek B, Jachymova M et al (2019) Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy. Herz 44(4):347\u2013353","journal-title":"Herz"},{"issue":"2","key":"587_CR115","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000487396","volume":"27","author":"SS Y\u0131ld\u0131z","year":"2018","unstructured":"Y\u0131ld\u0131z SS, Sahin I, Cetinkal G, Aksan G, Kucuk SH, Keskin K et al (2018) Usefulness of serum omentin-1 levels for the prediction of adverse cardiac events in patients with hypertrophic cardiomyopathy. Med Princ Pract 27(2):107\u2013114","journal-title":"Med Princ Pract"},{"issue":"2","key":"587_CR116","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jjcc.2011.11.008","volume":"59","author":"H Kitaoka","year":"2012","unstructured":"Kitaoka H, Kubo T, Baba Y, Yamasaki N, Matsumura Y, Furuno T et al (2012) Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy. J Cardiol 59(2):209\u2013214","journal-title":"J Cardiol"},{"issue":"2","key":"587_CR117","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/eurheartj\/ehn538","volume":"30","author":"F Cambronero","year":"2009","unstructured":"Cambronero F, Mar\u00edn F, Roldan V, Hernandez-Romero D, Valdes M, Lip GY (2009) Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J 30(2):139\u2013151","journal-title":"Eur Heart J"},{"issue":"4","key":"587_CR118","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1253\/circj.CJ-10-0782","volume":"75","author":"T Kubo","year":"2011","unstructured":"Kubo T, Kitaoka H, Okawa M, Yamanaka S, Hirota T, Baba Y et al (2011) Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy. Circ J 75(4):919\u2013926","journal-title":"Circ J"},{"issue":"24","key":"587_CR119","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","volume":"61","author":"JB Geske","year":"2013","unstructured":"Geske JB, McKie PM, Ommen SR, Sorajja P (2013) B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. J Am Coll Cardiol 61(24):2456\u20132460","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"587_CR120","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1536\/ihj.17-507","volume":"59","author":"H-J Yang","year":"2018","unstructured":"Yang H-J, Liu X, Qu C, Shi S-B, Liang J-J, Yang B (2018) Usefulness of red blood cell distribution width to predict heart failure hospitalization in patients with hypertrophic cardiomyopathy. Int Heart J 59(4):779\u2013785","journal-title":"Int Heart J"},{"issue":"2","key":"587_CR121","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jjcc.2008.07.003","volume":"52","author":"K Oka","year":"2008","unstructured":"Oka K, Tsujino T, Nakao S, Lee-Kawabata M, Ezumi A, Masai M et al (2008) Symptomatic ventricular tachyarrhythmia is associated with delayed gadolinium enhancement in cardiac magnetic resonance imaging and with elevated plasma brain natriuretic peptide level in hypertrophic cardiomyopathy. J Cardiol 52(2):146\u2013153","journal-title":"J Cardiol"},{"issue":"4","key":"587_CR122","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011075","volume":"8","author":"C Song","year":"2019","unstructured":"Song C, Wang S, Guo Y, Zheng X, Lu J, Fang X et al (2019) Preoperative NT-proBNP predicts midterm outcome after septal myectomy. J Am Heart Assoc 8(4):e011075","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"587_CR123","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/1354750X.2018.1474261","volume":"23","author":"M Gawor","year":"2018","unstructured":"Gawor M, \u015apiewak M, Kubik A, Wr\u00f3bel A, Luty\u0144ska A, Marczak M et al (2018) Circulating biomarkers of hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy assessed by cardiac magnetic resonance. Biomarkers 23(7):676\u2013682","journal-title":"Biomarkers"},{"issue":"19","key":"587_CR124","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","volume":"74","author":"S Neubauer","year":"2019","unstructured":"Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF et al (2019) Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry. J Am Coll Cardiol 74(19):2333\u20132345","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"587_CR125","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.amjcard.2013.04.060","volume":"112","author":"T Kawasaki","year":"2013","unstructured":"Kawasaki T, Sakai C, Harimoto K, Yamano M, Miki S, Kamitani T (2013) Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Am J Cardiol 112(6):867\u2013872","journal-title":"Am J Cardiol"},{"issue":"7","key":"587_CR126","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cardfail.2012.04.005","volume":"18","author":"F Fernandes","year":"2012","unstructured":"Fernandes F, Arteaga-Fernandez E, de Oliveira AM, Buck P, Marsiglia JDC, Matsumoto A et al (2012) Plasma pro-B-type natriuretic peptide testing as a screening method for hypertrophic cardiomyopathy. J Cardiac Fail 18(7):564\u2013568","journal-title":"J Cardiac Fail"},{"issue":"3","key":"587_CR127","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1536\/ihj.18-598","volume":"60","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Yuan J, Wang Y, Qiao S (2019) Predictive values of apelin for myocardial fibrosis in hypertrophic cardiomyopathy. Int Heart J 60(3):648\u2013655","journal-title":"Int Heart J"},{"key":"587_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2261-13-70","volume":"13","author":"CM McGorrian","year":"2013","unstructured":"McGorrian CM, Lyster S, Roy A, Tarrant H, Codd M, Doran P et al (2013) Use of a highly-sensitive cardiac troponin I assay in a screening population for hypertrophic cardiomyopathy: a case-referent study. BMC Cardiovasc Disord 13:1\u20139","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"587_CR129","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1002\/ehf2.12852","volume":"7","author":"T Kubo","year":"2020","unstructured":"Kubo T, Ochi Y, Baba Y, Sugiura K, Takahashi A, Hirota T et al (2020) Elevation of high-sensitivity cardiac troponin T and left ventricular remodelling in hypertrophic cardiomyopathy. ESC Heart Fail 7(6):3593\u20133600","journal-title":"ESC Heart Fail"},{"issue":"12","key":"587_CR130","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cardfail.2010.07.245","volume":"16","author":"V Moreno","year":"2010","unstructured":"Moreno V, Hern\u00e1ndez-Romero D, Vilchez JA, Garc\u00eda-Honrubia A, Cambronero F, Casas T et al (2010) Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J Cardiac Fail 16(12):950\u2013956","journal-title":"J Cardiac Fail"},{"key":"587_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2019.107150","volume":"43","author":"C Yang","year":"2019","unstructured":"Yang C, Qiao S, Song Y, Liu Y, Tang Y, Deng L et al (2019) Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol 43:107150","journal-title":"Cardiovasc Pathol"},{"issue":"12","key":"587_CR132","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4070\/kcj.2009.39.12.519","volume":"39","author":"CY Shim","year":"2009","unstructured":"Shim CY, Ha J-W, Choi E-Y, Lee H-J, Moon S-H, Kim J-M et al (2009) Relationship between serum biochemical markers of myocardial fibrosis and diastolic function at rest and with exercise in hypertrophic cardiomyopathy. Korean Circ J 39(12):519\u2013524","journal-title":"Korean Circ J"},{"issue":"6","key":"587_CR133","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa1002659","volume":"363","author":"CY Ho","year":"2010","unstructured":"Ho CY, L\u00f3pez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P et al (2010) Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363(6):552\u2013563","journal-title":"N Engl J Med"},{"issue":"6","key":"587_CR134","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.amjms.2018.08.013","volume":"356","author":"S Emet","year":"2018","unstructured":"Emet S, Dadashov M, Sonsoz MR, Cakir MO, Yilmaz M, Elitok A et al (2018) Galectin-3: a novel biomarker predicts sudden cardiac death in hypertrophic cardiomyopathy. Am J Med Sci 356(6):537\u2013543","journal-title":"Am J Med Sci"},{"issue":"10","key":"587_CR135","doi-asserted-by":"publisher","first-page":"997","DOI":"10.5603\/KP.a2017.0118","volume":"75","author":"M Gawor","year":"2017","unstructured":"Gawor M, \u015apiewak M, Janas J, Ko\u017cuch K, Wr\u00f3bel A, Mazurkiewicz \u0141 et al (2017) The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Polish Heart J (Kardiologia Polska) 75(10):997\u20131004","journal-title":"Polish Heart J (Kardiologia Polska)"},{"issue":"12","key":"587_CR136","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s10554-016-0958-1","volume":"32","author":"D-J Hu","year":"2016","unstructured":"Hu D-J, Xu J, Du W, Zhang J-X, Zhong M, Zhou Y-N (2016) Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients. Int J Cardiovasc Imaging 32(12):1725\u20131733","journal-title":"Int J Cardiovasc Imaging"},{"issue":"5","key":"587_CR137","first-page":"344","volume":"16","author":"SY T\u00fcl\u00fcce","year":"2016","unstructured":"T\u00fcl\u00fcce SY, T\u00fcl\u00fcce K, \u00c7il Z, Emren SV, Akyildiz ZI, Ergene O (2016) Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function. Anatol J Cardiol 16(5):344","journal-title":"Anatol J Cardiol"},{"issue":"5","key":"587_CR138","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1136\/hrt.2009.172320","volume":"96","author":"K Unno","year":"2010","unstructured":"Unno K, Shibata R, Izawa H, Hirashiki A, Murase Y, Yamada T et al (2010) Adiponectin acts as a positive indicator of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Heart 96(5):357\u2013361","journal-title":"Heart"},{"issue":"1","key":"587_CR139","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1536\/ihj.51.51","volume":"51","author":"H Kitaoka","year":"2010","unstructured":"Kitaoka H, Kubo T, Okawa M, Yamasaki N, Matsumura Y, Nishinaga M et al (2010) Plasma adiponectin levels and left ventricular remodeling in hypertrophic cardiomyopathy. Int Heart J 51(1):51\u201355","journal-title":"Int Heart J"},{"issue":"1","key":"587_CR140","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/clc.22602","volume":"40","author":"I Sahin","year":"2017","unstructured":"Sahin I, Gungor B, Ozkaynak B, Uzun F, K\u00fc\u00e7\u00fck SH, Avci II et al (2017) Higher copeptin levels are associated with worse outcome in patients with hypertrophic cardiomyopathy. Clin Cardiol 40(1):32\u201337","journal-title":"Clin Cardiol"},{"issue":"3","key":"587_CR141","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1113\/EP088263","volume":"105","author":"X Duan","year":"2020","unstructured":"Duan X, Liu R, Luo XL, Gao XJ, Hu FH, Guo C et al (2020) The relationship between \u03b21-adrenergic and M2-muscarinic receptor autoantibodies and hypertrophic cardiomyopathy. Exp Physiol 105(3):522\u2013530","journal-title":"Exp Physiol"},{"key":"587_CR142","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10741-021-10084-y","volume":"27","author":"D Ntelios","year":"2022","unstructured":"Ntelios D, Georgiou E, Alexouda S, Malousi A, Efthimiadis G, Tzimagiorgis G (2022) A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy. Heart Fail Rev 27:281","journal-title":"Heart Fail Rev"},{"issue":"3","key":"587_CR143","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.amjcard.2015.11.016","volume":"117","author":"JL Blackshear","year":"2016","unstructured":"Blackshear JL, Kusumoto H, Safford RE, Wysokinska E, Thomas CS, Waldo OA et al (2016) Usefulness of von Willebrand factor activity indexes to predict therapeutic response in hypertrophic cardiomyopathy. Am J Cardiol 117(3):436\u2013442","journal-title":"Am J Cardiol"},{"issue":"15","key":"587_CR144","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1161\/CIRCULATIONAHA.108.786681","volume":"118","author":"T Le Tourneau","year":"2008","unstructured":"Le Tourneau T, Susen S, Caron C, Millaire A, Mar\u00e9chaux S, Polge A-S et al (2008) Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction. Circulation 118(15):1550\u20131557","journal-title":"Circulation"},{"issue":"1","key":"587_CR145","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/j.thromres.2010.01.010","volume":"126","author":"F Cambronero","year":"2010","unstructured":"Cambronero F, Vilchez JA, Garc\u00eda-Honrubia A, Ruiz-Espejo F, Moreno V, Hern\u00e1ndez-Romero D et al (2010) Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. Thromb Res 126(1):e46\u2013e50","journal-title":"Thromb Res"},{"issue":"6","key":"587_CR146","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","volume":"143","author":"S Saberi","year":"2021","unstructured":"Saberi S, Cardim N, Yamani M, Schulz-Menger J, Li W, Florea V et al (2021) Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation 143(6):606\u2013608","journal-title":"Circulation"},{"issue":"2","key":"587_CR147","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG et al (2022) Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol 80(2):95\u2013108","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"587_CR148","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027618","volume":"11","author":"EL Matthia","year":"2022","unstructured":"Matthia EL, Setteducato ML, Elzeneini M, Vernace N, Salerno M, Kramer CM et al (2022) Circulating biomarkers in hypertrophic cardiomyopathy. J Am Heart Assoc 11(23):e027618","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"587_CR149","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","volume":"131","author":"MS Maron","year":"2018","unstructured":"Maron MS, Chan RH, Kapur NK, Jaffe IZ, McGraw AP, Kerur R et al (2018) Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy. Am J Med 131(7):837\u2013841","journal-title":"Am J Med"},{"issue":"2","key":"587_CR150","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","volume":"3","author":"A Axelsson","year":"2015","unstructured":"Axelsson A, Iversen K, Vejlstrup N, Ho C, Norsk J, Langhoff L et al (2015) Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 3(2):123\u2013131","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"25","key":"587_CR151","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","volume":"78","author":"AM Dybro","year":"2021","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH (2021) Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 78(25):2505\u20132517","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"587_CR152","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jacc.2022.02.024","volume":"79","author":"AM Dybro","year":"2022","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, Ladefoged BT, Andersen MJ, Jensen MK et al (2022) Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 79(16):1565\u20131575","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"587_CR153","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","volume":"127","author":"R Coppini","year":"2013","unstructured":"Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F et al (2013) Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 127(5):575\u2013584","journal-title":"Circulation"},{"issue":"1","key":"587_CR154","doi-asserted-by":"publisher","first-page":"e004124","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","volume":"11","author":"I Olivotto","year":"2018","unstructured":"Olivotto I, Camici PG, Merlini PA, Rapezzi C, Patten M, Climent V et al (2018) Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail 11(1):e004124","journal-title":"Circ Heart Fail"},{"issue":"24","key":"587_CR155","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","volume":"75","author":"EJ Rowin","year":"2020","unstructured":"Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S et al (2020) Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. J Am Coll Cardiol 75(24):3033\u20133043","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"587_CR156","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/aor.12157","volume":"38","author":"PN Mohite","year":"2014","unstructured":"Mohite PN, Zych B, Banner NR, Simon AR (2014) Refractory heart failure dependent on short-term mechanical circulatory support: what next? Heart transplant or long-term ventricular assist device. Artif Organs 38(4):276\u2013281","journal-title":"Artif Organs"},{"issue":"19","key":"587_CR157","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1161\/CIRCULATIONAHA.115.015085","volume":"133","author":"C MacIntyre","year":"2016","unstructured":"MacIntyre C, Lakdawala NK (2016) Management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 133(19):1901\u20131905","journal-title":"Circulation"},{"key":"587_CR158","doi-asserted-by":"publisher","first-page":"1429230","DOI":"10.3389\/fcvm.2024.1429230","volume":"11","author":"DS Kim","year":"2024","unstructured":"Kim DS, Chu EL, Keamy-Minor EE, Paranjpe ID, Tang WL, O\u2019Sullivan JW et al (2024) One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy. Front Cardiovasc Med 11:1429230","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"587_CR159","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030607","volume":"13","author":"A Masri","year":"2024","unstructured":"Masri A, Lester SJ, Stendahl JC, Hegde SM, Sehnert AJ, Balaratnam G et al (2024) Long-term safety and efficacy of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy: interim results of the PIONEER-OLE Study. J Am Heart Assoc 13(8):e030607","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"587_CR160","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","volume":"141","author":"CN Toepfer","year":"2020","unstructured":"Toepfer CN, Garfinkel AC, Venturini G, Wakimoto H, Repetti G, Alamo L et al (2020) Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation 141(10):828\u2013842","journal-title":"Circulation"},{"issue":"6273","key":"587_CR161","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC et al (2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351(6273):617\u2013621","journal-title":"Science"},{"issue":"40","key":"587_CR162","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","volume":"292","author":"RF Kawas","year":"2017","unstructured":"Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM (2017) A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem 292(40):16571\u201316577","journal-title":"J Biol Chem"},{"issue":"35","key":"587_CR163","doi-asserted-by":"publisher","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","volume":"115","author":"RL Anderson","year":"2018","unstructured":"Anderson RL, Trivedi DV, Sarkar SS, Henze M, Ma W, Gong H et al (2018) Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci 115(35):E8143\u2013E8152","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"587_CR164","doi-asserted-by":"publisher","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","volume":"320","author":"PO Awinda","year":"2021","unstructured":"Awinda PO, Watanabe M, Bishaw Y, Huckabee AM, Agonias KB, Kazmierczak K et al (2021) Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 320(2):H881\u2013H890","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10253","key":"587_CR165","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759\u2013769","journal-title":"Lancet"},{"issue":"25","key":"587_CR166","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","volume":"78","author":"SM Hegde","year":"2021","unstructured":"Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF et al (2021) Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 78(25):2518\u20132532","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"587_CR167","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168407","volume":"11","author":"JA Stern","year":"2016","unstructured":"Stern JA, Markova S, Ueda Y, Kim JB, Pascoe PJ, Evanchik MJ et al (2016) A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy. PLoS ONE 11(12):e0168407","journal-title":"PLoS ONE"},{"issue":"6","key":"587_CR168","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","volume":"49","author":"MP Grillo","year":"2019","unstructured":"Grillo MP, Erve JC, Dick R, Driscoll JP, Haste N, Markova S et al (2019) In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica 49(6):718\u2013733","journal-title":"Xenobiotica"},{"key":"587_CR169","first-page":"24","volume":"11","author":"V Perera","year":"2022","unstructured":"Perera V, Gretler D, Seroogy J, Chiang M, Palmisano M, Florea V (2022) Pharmacokinetic drug-drug interaction study of mavacamten with verapamil in healthy subjects. Clin Pharm Drug Dev 11:24\u201325","journal-title":"Clin Pharm Drug Dev"},{"issue":"11","key":"587_CR170","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"SB Heitner","year":"2019","unstructured":"Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D et al (2019) Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med 170(11):741\u2013748","journal-title":"Ann Intern Med"},{"key":"587_CR171","first-page":"A13962-A","volume":"140","author":"SB Heitner","year":"2019","unstructured":"Heitner SB, Lester S, Wang A, Hegde SM, Fang L, Balaratnam G et al (2019) Precision pharmacological treatment for obstructive hypertrophic cardiomyopathy with mavacamten: one-year results from PIONEER-OLE. Circulation 140:A13962-A","journal-title":"Circulation"},{"issue":"10","key":"587_CR172","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jacc.2022.01.005","volume":"79","author":"GH Tison","year":"2022","unstructured":"Tison GH, Siontis KC, Abreau S, Attia Z, Agarwal P, Balasubramanyam A et al (2022) Assessment of disease status and treatment response with artificial intelligence\u2014enhanced electrocardiography in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 79(10):1032\u20131034","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"587_CR173","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.2737","volume":"25","author":"MT Wheeler","year":"2023","unstructured":"Wheeler MT, Jacoby D, Elliott PM, Saberi S, Hegde SM, Lakdawala NK et al (2023) Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Eur J Heart Fail 25(2):260\u2013270","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"587_CR174","first-page":"567","volume":"12","author":"A Wang","year":"2024","unstructured":"Wang A, Spertus JA, Wojdyla DM, Abraham TP, Nilles EK, Owens AT et al (2024) Mavacamten for obstructive hypertrophic cardiomyopathy with or without hypertension: post-hoc analysis of the EXPLORER-HCM trial. Heart Fail 12(3):567\u2013579","journal-title":"Heart Fail"},{"key":"587_CR175","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/DDDT.S368590","volume":"17","author":"T Dong","year":"2023","unstructured":"Dong T, Alencherry B, Ospina S, Desai MY (2023) Review of mavacamten for obstructive hypertrophic cardiomyopathy and future directions. Drug Des Devel Ther 17:1097\u20131106","journal-title":"Drug Des Devel Ther"},{"key":"587_CR176","doi-asserted-by":"publisher","first-page":"1227470","DOI":"10.3389\/fphar.2023.1227470","volume":"14","author":"X Zhao","year":"2023","unstructured":"Zhao X, Liu H, Tian W, Fang L, Yu M, Wu X et al (2023) Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study. Front Pharmacol 14:1227470","journal-title":"Front Pharmacol"},{"issue":"19","key":"587_CR177","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","volume":"64","author":"C Chuang","year":"2021","unstructured":"Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X et al (2021) Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem 64(19):14142\u201314152","journal-title":"J Med Chem"},{"key":"587_CR178","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","volume":"30","author":"A Masri","year":"2024","unstructured":"Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM et al (2024) Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, Cohort 4. J Cardiac Fail 30:1439","journal-title":"J Cardiac Fail"},{"key":"587_CR179","first-page":"A332","volume":"125","author":"DT Hwee","year":"2019","unstructured":"Hwee DT, Hartman JJ, Wang J, Wu Y, Schaletzky J, Paliwal P et al (2019) Pharmacologic characterization of the cardiac myosin inhibitor, CK-3773274: a potential therapeutic approach for hypertrophic cardiomyopathy. Circ Res 125:A332","journal-title":"Circ Res"},{"issue":"3","key":"587_CR180","doi-asserted-by":"publisher","first-page":"596a","DOI":"10.1016\/j.bpj.2019.11.3225","volume":"118","author":"JJ Hartman","year":"2020","unstructured":"Hartman JJ, Hwee DT, Wang J, Wu Y, Schaletzky J, Paliwal P et al (2020) Characterization of the cardiac myosin inhibitor CK-3773274: a potential therapeutic approach for hypertrophic cardiomyopathy. Biophys J 118(3):596a","journal-title":"Biophys J"},{"key":"587_CR181","doi-asserted-by":"publisher","first-page":"A615","DOI":"10.1161\/res.125.suppl_1.615","volume":"125","author":"DT Hwee","year":"2019","unstructured":"Hwee DT, Wu Y, Cremin P, Morgan BP, Malik FI, Chin ER (2019) The cardiac myosin inhibitor, CK-3773274, reduces contractility in the R403q mouse model of hypertrophic cardiomyopathy. Circ Res 125:A615","journal-title":"Circ Res"},{"key":"587_CR182","unstructured":"Cremin P, Xu D, Zamora J, Cheung J, Leung K, Chuang G, et al., (eds) (2020) In vivo pharmacokinetic characterization of CK-3773274. A Novel Cardiac Myosin Inhibitor. In: Abstract presented at the 2020 American Association of pharmaceutical scientists meeting and exposition"},{"issue":"1","key":"587_CR183","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","volume":"81","author":"MS Maron","year":"2023","unstructured":"Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A et al (2023) Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 81(1):34\u201345","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"587_CR184","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0033-0620(68)90011-X","volume":"11","author":"LS Cohen","year":"1968","unstructured":"Cohen LS, Braunwald E (1968) Chronic beta adrenergic receptor blockade in the treatment of idiopathic hypertrophic subaortic stenosis. Prog Cardiovasc Dis 11(3):211\u2013221","journal-title":"Prog Cardiovasc Dis"},{"key":"587_CR185","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.amjcard.2022.06.007","volume":"180","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Dearani JA, Smedira NG, Schaff HV, Wang S, Rastegar H et al (2022) Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC expert panel. Am J Cardiol 180:124\u2013139","journal-title":"Am J Cardiol"},{"issue":"24","key":"587_CR186","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","volume":"72","author":"A Batzner","year":"2018","unstructured":"Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H (2018) Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 72(24):3087\u20133094","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"587_CR187","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","volume":"27","author":"CY Ho","year":"2021","unstructured":"Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM et al (2021) Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med 27(10):1818\u20131824","journal-title":"Nat Med"},{"issue":"6","key":"587_CR188","doi-asserted-by":"publisher","first-page":"e006853","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","volume":"13","author":"CY Ho","year":"2020","unstructured":"Ho CY, Olivotto I, Jacoby D, Lester SJ, Roe M, Wang A et al (2020) Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy. Circ Heart Fail 13(6):e006853","journal-title":"Circ Heart Fail"},{"issue":"21","key":"587_CR189","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM et al (2020) Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 75(21):2649\u20132660","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl_1","key":"587_CR190","doi-asserted-by":"publisher","first-page":"A9685-A","DOI":"10.1161\/circ.144.suppl_1.9685","volume":"144","author":"A Owens","year":"2021","unstructured":"Owens A, Sherrid MV, Wong TC, Bach RG, Wever-Pinzon O, Rigolli M et al (2021) Long-term efficacy and safety of mavacamten in patients with non-obstructive hypertrophic cardiomyopathy: interim results from the MAVERICK-LTE cohort of the MAVA-LTE study. Circulation 144(Suppl_1):A9685-A","journal-title":"Circulation"},{"issue":"8","key":"587_CR191","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0735-1097(23)00770-2","volume":"81","author":"S Saberi","year":"2023","unstructured":"Saberi S, Kramer CM, Oreziak A, Masri A, Villa RB, Abraham TP et al (2023) 96-week cardiac magnetic resonance (CMR) results of treatment with mavacamten from the explorer cohort of the mava-long-term extension (LTE) study in patients (PTS) with obstructive hypertrophic cardiomyopathy (HCM). J Am Coll Cardiol 81(8):326","journal-title":"J Am Coll Cardiol"},{"issue":"10293","key":"587_CR192","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","volume":"397","author":"JA Spertus","year":"2021","unstructured":"Spertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S et al (2021) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397(10293):2467\u20132475","journal-title":"Lancet"},{"issue":"8","key":"587_CR193","first-page":"531","volume":"10","author":"M Nassif","year":"2022","unstructured":"Nassif M, Fine JT, Dolan C, Reaney M, Addepalli P, Allen VD et al (2022) Validation of the Kansas City cardiomyopathy questionnaire in symptomatic obstructive hypertrophic cardiomyopathy. Heart Failure 10(8):531\u2013539","journal-title":"Heart Failure"},{"issue":"1","key":"587_CR194","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/13696998.2021.2011301","volume":"25","author":"J Xie","year":"2022","unstructured":"Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP (2022) Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial. J Med Econ 25(1):51\u201358","journal-title":"J Med Econ"},{"issue":"1","key":"587_CR195","first-page":"164","volume":"12","author":"F Rader","year":"2024","unstructured":"Rader F, Or\u0119ziak A, Choudhury L, Saberi S, Fermin D, Wheeler MT et al (2024) Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort. Heart Fail 12(1):164\u2013177","journal-title":"Heart Fail"},{"issue":"1","key":"587_CR196","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14779072.2023.2159811","volume":"21","author":"T Dong","year":"2023","unstructured":"Dong T, Nissen S, Ospina S, Desai MY (2023) An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Expert Rev Cardiovasc Ther 21(1):5\u201313","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-024-00587-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-024-00587-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-024-00587-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T18:02:45Z","timestamp":1733594565000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-024-00587-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":196,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1186\/s43044-024-00587-y","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflicts of interest concerning the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}